10-Q: DiaMedica Therapeutics Q1 2026 Update: Clinical Trials Progress Amidst Financial Losses

DiaMedica Therapeutics reports on progress in its DM199 clinical trials for preeclampsia and acute ischemic stroke, while continuing to incur operating losses and seeking additional financing.

Summary

• DiaMedica Therapeutics Inc. filed its Form 10-Q for the quarterly period ended March 31, 2026.
• The company is focused on developing DM199 for preeclampsia (PE), fetal growth restriction (FGR), and acute ischemic stroke (AIS).
• The Phase 2 investigator-sponsored study for PE and FGR in South Africa has shown DM199 to be safe and well-tolerated with clinically relevant pharmacodynamic activity, including sustained blood pressure reductions.
• Enrollment and site activations for the Phase 2/3 ReMEDy2 trial for AIS are experiencing delays attributed to hospital staffing shortages and other factors.
• The company incurred a net loss of $10.0 million for the quarter, with an accumulated deficit of $182.8 million.
• As of March 31, 2026, DiaMedica had $51.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next 12 months.
• The company anticipates moderate increases in quarterly expenses due to ongoing clinical development and expansion.
• DiaMedica is preparing for a global Phase 2 study in early-onset PE, having received Health Canada approval and planning UK expansion.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment score due to increased net losses, higher cash burn from operations, and significant delays in key clinical trials, despite some positive interim data.

Positives

• Interim results from the Phase 2 PE/FGR study in South Africa (N=28) demonstrated DM199 is safe, well-tolerated, and shows clinically relevant pharmacodynamic activity with no evidence of placental transfer.
• Potentially therapeutic dose levels in the PE study showed rapid, statistically significant, and sustained reductions in blood pressure up to 24 hours post-infusion.
• Health Canada approved the initiation of a global Phase 2 study of DM199 in early-onset PE.
• The company has $51.3 million in cash, cash equivalents, and marketable securities, sufficient to fund operations for at least the next 12 months.
• Common shares issued upon exercise of stock options and vesting of RSUs contributed to paid-in capital.

Negatives

• Net loss for the three months ended March 31, 2026, was $10.0 million, compared to $7.7 million in the prior year period.
• Accumulated deficit reached $182.8 million as of March 31, 2026.
• The ReMEDy2 trial for AIS is experiencing slower than expected site activations and enrollment.
• The company expects to continue incurring substantial operating losses for at least the next few years.
• Cash used in operating activities increased to $9.1 million for the three months ended March 31, 2026, from $7.1 million in the prior year period.
• The company requires substantial additional capital to fund ongoing R&D, clinical studies, and regulatory activities.

Risks

• The FDA's acceptance of study data from clinical trials conducted outside the United States may be subject to conditions or may not be accepted, potentially requiring additional costly and time-consuming trials.
• Slower than expected site activations and enrollment in the ReMEDy2 trial for AIS are attributed to hospital staffing shortages, protocol inclusion/exclusion criteria, logistics for discharged patients, prior hypotension events, use of AI/telemedicine by smaller hospitals, and competition for research staff.
• Failure to resolve issues impacting site activations and enrollment in the ReMEDy2 trial may result in further delays and difficulty in forecasting enrollment.
• The adaptive design of the ReMEDy2 trial means the final sample size could range from 300 to 728 patients, impacting timelines and costs.
• The company faces uncertainties regarding regulatory applications, filing and approval timelines, and potential requests for additional studies from government agencies.
• There is a risk of future adverse events or unfavorable results from current or future trials that could negatively impact the development program.
• The company has not completed development of any product candidate and does not generate revenue from commercial sales, with DM199 not expected to be commercially available for at least three to four years, if at all.
• The company may require significant additional capital and there is no assurance it will be able to obtain it on favorable terms or at all, especially if clinical data is not positive or market conditions deteriorate.
• The company may need to scale back operations, license rights, or cease operations if adequate funding is not available.
• The FDA requested an additional non-clinical ePPND study for the PE program, and preliminary results in rabbits suggest an antibody response to DM199, preventing completion of the study in that model.

Future Outlook

DiaMedica expects to continue incurring significant operating losses for at least the next few years as it advances its DM199 clinical development programs for PE, FGR, and AIS. Quarterly expenses are anticipated to increase moderately due to ongoing clinical trials, global expansion, and team growth. The company expects its current cash resources to fund planned operations for at least the next 12 months, but anticipates needing substantial additional capital for further development, regulatory activities, and potential commercialization.

Management Comments

• Rick Pauls, President and Chief Executive Officer, certified that the report fully complies with SEC requirements and fairly presents the company's financial condition and results of operations.
• Scott Kellen, Chief Financial Officer, certified that the report fully complies with SEC requirements and fairly presents the company's financial condition and results of operations.

Industry Context

StockSavvy.ai notes that DiaMedica Therapeutics operates in the highly competitive and regulated biopharmaceutical sector, focusing on rare and severe diseases. The company's reliance on clinical trial progress and regulatory approvals, coupled with significant R&D expenses and a long path to potential commercialization, is typical for companies at this stage. The delays in the ReMEDy2 trial due to external factors like staffing shortages highlight common operational challenges faced by clinical-stage biotechs.

Comparison to Industry Standards

• The net loss of $10.0 million for the quarter and an accumulated deficit of $182.8 million are substantial but not uncommon for clinical-stage biopharmaceutical companies investing heavily in R&D, such as those developing novel therapies for conditions like preeclampsia and stroke.
• The cash burn rate of approximately $9.1 million per quarter from operations, while significant, is managed by maintaining a cash and marketable securities balance of $51.3 million, aiming for at least a 12-month runway, a common benchmark for such companies.
• The company's reliance on equity financings for capital, with $86.2 million still available under an ATM program, is a standard practice in the industry to fund development pipelines when product revenues are not yet generated.

Legal Proceedings

• The company is not currently engaged in or aware of any threatened legal actions.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financings, continued uncertainty regarding clinical trial success and path to commercialization, and negative impact from increased net losses and cash burn.
• Employees: Continued employment dependent on securing adequate funding and successful development progress; potential for increased workload due to trial expansion and mitigation efforts.
• Creditors: No significant debt mentioned, so direct impact is minimal, but overall financial health impacts long-term viability.
• Suppliers/Service Providers: Continued engagement for clinical trial support, R&D services, and manufacturing, dependent on funding availability.

Next Steps

• Continue advancing DM199 through clinical trials for PE, FGR, and AIS.
• Complete the Phase 2 investigator-sponsored study for PE and FGR.
• Initiate and conduct the global Phase 2 study of DM199 in early-onset PE in North America and the UK.
• Continue efforts to mitigate delays and enhance site activations and enrollment in the ReMEDy2 trial for AIS.
• Complete the interim analysis for the ReMEDy2 trial in Q4 2026.
• Address the FDA's request for an additional non-clinical ePPND study for the PE program, potentially in a different animal model.
• Seek additional financing to fund ongoing operations and development activities.

Key Dates

Recommendation

The company shows promising early-stage clinical data for DM199 in preeclampsia, but faces significant headwinds with delays in its acute ischemic stroke trial, increasing operational losses, and a clear need for substantial future financing. While the potential of DM199 is a positive, the execution risks and financial uncertainties warrant a cautious 'hold' stance until trial progress becomes more predictable and funding is secured.

Keywords

DiaMedica Therapeutics, Form 10-Q, DM199, preeclampsia, fetal growth restriction, acute ischemic stroke, clinical trials, biopharmaceutical, FDA, Nasdaq, net loss, cash burn, financing